About The Study: This article discusses a recent revision of the Alzheimer Association criteria to define Alzheimer disease (AD) as a purely biological entity, which raises concerns that if diagnosis of AD can be reduced to the sole presence of AD core 1 biomarkers, major uncertainty and variability in the clinical prognosis of patients diagnosed with AD may be introduced.
Corresponding Author: To contact the corresponding author, Bruno Dubois, MD, MSc, email bruno.dubois@aphp.fr .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2024.3770)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 17th Clinical Trials on Alzheimer’s Disease conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.3770?guestAccessKey=5d249549-8367-4844-b4c4-b4b21eac4863&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110124
JAMA Neurology